skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

13 Total results for product and free and sample content found

Pink Sheet

US Drug Pricing Reform Post-Election: Scenarios To Consider And Lessons Learned

US Election Drug Pricing Reform

Regardless of the outcomes of the US elections, drug pricing is likely to take a back seat to COVID as policy focus. But the pandemic does offer pharma an opportunity for partnerships with payers on health outcomes. Commonwealth Fund’s Liz Fowler, South Capitol’s John O’Brien and ICER’s Steve Pearson discuss where drug pricing stands in public opinion, whether policies embraced by President Trump will have staying power, and the conditions needed in the policy environment for major change.

Topic US Election 2020 Policy & Regulation Drug Pricing

Pink Sheet

Biden Administration May Push Rx Pricing To Back Burner With Senate That Stays Pharma Friendly

Biden Administration Rx Pricing

A Biden Administration with near-term priorities other than drug pricing and a Republican-controlled Senate dedicated to blocking any legislation that would enact government price controls is a relatively positive outcome for industry

Topic US Election 2020 Drug Pricing

Pink Sheet

Biden, Germany And Bringing A National Drug Pricing Negotiation Process To US

Biden US Election 2020 final debate

Germany uses government facilitated price negotiations between publicly funded insurers and manufacturers that are based on an independent assessment of how much added value a drug provides.

Topic US Election 2020 Drug Pricing

Pink Sheet

'Like Water': Pharma Avoids Much Scrutiny In Messy Presidential Debate

US Election 2020 Debate

Trump and Biden trade barbs in debate that included a suggestion by the president that coronavirus vaccine development delays are political and saw Biden questioned on whether he was contributing to vaccine hesitancy.

Topic US Election 2020 Drug Pricing Policy & Regulation

Scrip

Quick Listen: Scrip's Five Must-Know Things

Scrip August Podcast

Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.

Topic Clinical Trials Drug Pricing Research & Development

Pink Sheet

Six Pharma CEOs To Testify In House as Democrats, Trump Compete For Attention On Drug Pricing

US Election Drug Pricing Debate

While neither party is likely to make any big policy changes this year, the action from both sides of the aisle indicates politicians still see going after pharma as a winning issue with voters even as polls show voters are focused elsewhere.

Topic US Election 2020 Drug Pricing

Pink Sheet

'March In' Plan Unveiled By Democratic Think Tank: A Battle Biopharma Would Welcome?

Trump Biden US Elections

In sign of how much has changed in four years, industry might be better off if Biden takes CAP’s advice and launches ‘march-in’ actions to address pricing of COVID products.

Topic US Election 2020 Drug Pricing

Pink Sheet

Biden's Drug Pricing Administrative Actions Could Focus On Medicare Demos

Joe Biden Drug Pricing

Center for American Progress suggests pricing reforms for the 'next Administration' in lieu of legislation.

Topic US Election 2020 Drug Pricing

Pink Sheet

Biopharma Needs A Deal On Drug Pricing As Shield Against Possible Democrat Wins - BIO's Greenwood

US Election Drug Pricing Shielding

Outgoing Biotechnology Innovation Organization CEO suggests consideration of price inflation caps instead of 'big discounts' in Medicare Part D and says that industry should fund a cap on beneficiary out-of-pocket costs in the program.

Topic US Election 2020 Drug Pricing Legislation

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: